Schizophrenia Inpatient – Kynexis 5356-CL-002
About the Study
For adults with schizophrenia who are clinically stable, but require treatment on their cognitive functioning.
The goal of this study is to assess the efficacy, safety, and tolerability of KYN-5356 on treating cognitive impairment in adults living with symptoms of schizophrenia.
This study is sponsored by Kynexis Therapeutics.
Eligibility
You may be eligible to participate in this study if you:
are between the ages of 18-55 years old
have a confirmed primary diagnosis of schizophrenia based on DSM-5 criteria
are currently clinically stable for at least 8 weeks prior to screening
must be on a stable and ongoing treatment with no more than 1 antipsychotic medication (excluding Clozapine and Cobenfy) for at least 2 months prior to screening
are willing to stay in our overnight 24-hour observation unit for the full length of the study
If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.
If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.